What's in Zhejiang Huahai Pharmaceutical Co., Ltd.'s pipeline?

Zhejiang Huahai Pharmaceutical Co., Ltd. has 3 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Zhejiang Huahai Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Ain Shams University, Eli Lilly and Company, Jefferson Clinic, P.C., Ministry of Health & Welfare, Korea, National Institute of Mental Health (NIMH).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/zhejiang-huahai-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Zhejiang Huahai Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zhejiang Huahai Pharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Levomilnacipran Hydrochloride Extended-Release Capsules	Levomilnacipran Hydrochloride Extended-Release Capsules	phase 3	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)	Psychiatry / Neurology
Duloxetine Hydrochloride Enteric Capsules	Duloxetine Hydrochloride Enteric Capsules	phase 3	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)	Psychiatry / Pain Management

Therapeutic area mix

Psychiatry / Neurology · 1
Psychiatry / Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams University · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Jefferson Clinic, P.C. · 1 shared drug class
Ministry of Health & Welfare, Korea · 1 shared drug class
National Institute of Mental Health (NIMH) · 1 shared drug class
New York State Psychiatric Institute · 1 shared drug class
North Dakota State University · 1 shared drug class
Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zhejiang Huahai Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Zhejiang Huahai Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zhejiang-huahai-pharmaceutical-co-ltd. Accessed 2026-05-18.